 - Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade 1 CTCAE v 4.03 prior to starting study drug. Patients with grade 2 peripheral neuropathy or any grade of alopecia, nail changes or skin changes are allowed to enter the study. 